Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 24.9% in January

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the target of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 289,881 shares, a decrease of 24.9% from the December 31st total of 385,797 shares. Approximately 1.1% of the company’s shares are sold short. Based on an average daily trading volume, of 346,754 shares, the short-interest ratio is currently 0.8 days. Based on an average daily trading volume, of 346,754 shares, the short-interest ratio is currently 0.8 days. Approximately 1.1% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $1.50.

Adial Pharmaceuticals Stock Down 0.3%

Shares of NASDAQ:ADIL opened at $0.21 on Monday. The company has a market capitalization of $5.92 million, a price-to-earnings ratio of -0.28 and a beta of 1.26. The company has a 50 day moving average of $0.26 and a two-hundred day moving average of $0.34. Adial Pharmaceuticals has a 52-week low of $0.21 and a 52-week high of $1.30.

Adial Pharmaceuticals (NASDAQ:ADIL) last announced its earnings results on Thursday, November 13th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. On average, equities analysts anticipate that Adial Pharmaceuticals will post -1.53 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Adial Pharmaceuticals stock. Citadel Advisors LLC purchased a new stake in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 143,791 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned about 0.60% of Adial Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 16.41% of the company’s stock.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.